메뉴 건너뛰기




Volumn 45, Issue 3, 2015, Pages 230-238

In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP

Author keywords

CYP; Diabetes mellitus; Induction; Inhibition; Metabolism; SGLT2

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3FB; CYTOCHROME P450 4A11; CYTOCHROME P450 4F2; TOFOGLIFLOZIN; UNCLASSIFIED DRUG; 6-((4-ETHYLPHENYL)METHYL)-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO(ISOBENZOFURAN-1(3H),2'-(2H)PYRAN)-3',4',5'-TRIOL; BENZHYDRYL DERIVATIVE; CARBON; COENZYME; CYTOCHROME P450 INHIBITOR; GLUCOSIDE; PROTEIN BINDING; RECOMBINANT PROTEIN; SODIUM GLUCOSE COTRANSPORTER 2;

EID: 84924076457     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.976296     Document Type: Article
Times cited : (23)

References (20)
  • 1
    • 10744232330 scopus 로고    scopus 로고
    • The conduct of in vitro and in vivo drug-drug interaction studies: A pharmaceutical research and manufacturers of america (phrma) perspective
    • Bjornsson TD, Callaghan JT, Einolf HJ, et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metabol Disposit 31:815-32.
    • (2003) Drug Metabol Disposit , vol.31 , pp. 815-832
    • Bjornsson, T.D.1    Callaghan, J.T.2    Einolf, H.J.3
  • 2
    • 58149357463 scopus 로고    scopus 로고
    • Sodium-glucose co-transporter-2 inhibitors: An emerging new class of oral antidiabetic drug
    • Idris I, Donnelly R. (2009). Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metabol 11:79-88.
    • (2009) Diabetes Obes Metabol , vol.11 , pp. 79-88
    • Idris, I.1    Donnelly, R.2
  • 3
    • 34147155657 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter inhibitors for diabetes
    • Isaji M. (2007) . Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 8:285-92.
    • (2007) Curr Opin Investig Drugs , vol.8 , pp. 285-292
    • Isaji, M.1
  • 4
    • 84924023506 scopus 로고    scopus 로고
    • Kowa Pharmaceutical Co. Ltd. [package insert]. Available from [Japanese] [last accessed 30 Oct 2014]
    • Kowa Pharmaceutical Co., Ltd. (2014). Deberza (tofogliflozin) [package insert]. Available from: http://www.kowa-souyaku.co.jp/upload/item/66/4-pt-167.pdf [Japanese] [last accessed 30 Oct 2014].
    • (2014) Deberza (Tofogliflozin)
  • 5
    • 10944238594 scopus 로고    scopus 로고
    • A novel missense mutation in slc5a2 encoding sglt2 underlies autosomal-recessive r enal glucosuria and aminoaciduria
    • Magen D, Sprecher E, Zelikovic I, Skorecki K. (2005). A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive r enal glucosuria and aminoaciduria. Kidney Int 67:34-41.
    • (2005) Kidney Int , vol.67 , pp. 34-41
    • Magen, D.1    Sprecher, E.2    Zelikovic, I.3    Skorecki, K.4
  • 6
    • 84874070590 scopus 로고    scopus 로고
    • Selective sglt2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo-or euglycemic conditions in rats
    • Nagata T, Fukazawa M, Honda K, et al. (2013a). Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo-or euglycemic conditions in rats. Am J Physiol Endocrinol Metab 304:E414-23.
    • (2013) Am J Physiol Endocrinol Metab , vol.304 , pp. E414-E423
    • Nagata, T.1    Fukazawa, M.2    Honda, K.3
  • 7
    • 84884554260 scopus 로고    scopus 로고
    • Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves ren al and pancreatic function in db/db mice
    • Nagata T, Fukuzawa T, Takeda M, et al. (2013b). Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves ren al and pancreatic function in db/db mice. Br J Pharmacol 170:519-31.
    • (2013) Br J Pharmacol , vol.170 , pp. 519-531
    • Nagata, T.1    Fukuzawa, T.2    Takeda, M.3
  • 8
    • 84866336965 scopus 로고    scopus 로고
    • Discovery of tofogliflozin, a novel c-Arylglucoside with an o-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (sglt2) inhibitor for the treatment of type 2 diabetes
    • Ohtake Y, Sato T, Kobayashi T, et al. (2012). Discovery of tofogliflozin, a novel C-Arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 55:7828-40.
    • (2012) J Med Chem , vol.55 , pp. 7828-7840
    • Ohtake, Y.1    Sato, T.2    Kobayashi, T.3
  • 9
    • 84924071356 scopus 로고    scopus 로고
    • [package insert]. Available from [Japanese]. [last accessed 30 Oct 2014]
    • SANOFI K. K. (2014). Apleway (tofogliflozin) [package insert]. Available from: http://e-mr.sanofi.co.jp/di/tenpu/apleway.pdf ?date= 20140523174259 [Japanese]. [last accessed 30 Oct 2014].
    • (2014) Apleway (Tofogliflozin)
    • Sanofi, K.K.1
  • 10
    • 10744229025 scopus 로고    scopus 로고
    • Molecular analysis of the sglt2 gene in patients with renal glucosuria
    • Santer R, Kinner M, Lassen CL, et al. (2003). Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14: 2873-82.
    • (2003) J Am Soc Nephrol , vol.14 , pp. 2873-2882
    • Santer, R.1    Kinner, M.2    Lassen, C.L.3
  • 11
    • 21744449237 scopus 로고    scopus 로고
    • Drug interactions of clinical importance with antihyperglycaemic agents: An update
    • Scheen AJ. 2005 Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 28, 601-31.
    • (2005) Drug Saf , vol.28 , pp. 601-631
    • Scheen, A.J.1
  • 12
    • 84878738942 scopus 로고    scopus 로고
    • A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (adme) of [(14)c]tofogliflozin after oral administration and concomitant intravenous microdose administration of [(13 )c]tofogliflozin in humans
    • Schwab D, Portron A, Backholer Z, et al. (2013). A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [(14)C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [(13 )C]tofogliflozin in humans. Clin Pharmacokinet 52: 463-73.
    • (2013) Clin Pharmacokinet , vol.52 , pp. 463-473
    • Schwab, D.1    Portron, A.2    Backholer, Z.3
  • 13
    • 84962967354 scopus 로고    scopus 로고
    • Tofogliflozin a selective sglt2 inhibitor exhibits highly favourable drug properties for use in patients with renal impairment and for combination with other medicines
    • 2012 Oct 1-5; Berlin, Germany. Diabetologia
    • Schwab D, Portron A, Fukushima Y, et al. (2012). Tofogliflozin a selective SGLT2 inhibitor exhibits highly favourable drug properties for use in patients with renal impairment and for combination with other medicines. Abstracts of the 48th EASD Annual Meeting of the European Association for the Study of Diabetes; 2012 Oct 1-5; Berlin, Germany. Diabetologia 55:S316.
    • (2012) Abstracts of the 48th EASD Annual Meeting of the European Association for the Study of Diabetes , vol.55 , pp. S316
    • Schwab, D.1    Portron, A.2    Fukushima, Y.3
  • 14
    • 84903119140 scopus 로고    scopus 로고
    • Effect of sglt2 inhibitors in a murine model of urinary tract infection with candida albicans
    • Suzuki M, Hiramatsu M, Fukazawa M, et al. (2014). Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans. Diabetes, Obes Metabol 16:622-7.
    • (2014) Diabetes, Obes Metabol , vol.16 , pp. 622-627
    • Suzuki, M.1    Hiramatsu, M.2    Fukazawa, M.3
  • 15
    • 84861536065 scopus 로고    scopus 로고
    • Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice
    • Suzuki M, Honda K, Fukazawa M, et al. (2012). Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341: 692-701.
    • (2012) J Pharmacol Exp Ther , vol.341 , pp. 692-701
    • Suzuki, M.1    Honda, K.2    Fukazawa, M.3
  • 16
    • 78651406659 scopus 로고    scopus 로고
    • Sglt2 mediates glucose reabsorption in the early proximal tubule
    • Vallo n V, Platt KA, Cunard R, et al. (2011). SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22: 104-12.
    • (2011) J Am Soc Nephrol , vol.22 , pp. 104-112
    • Vallon, V.1    Platt, K.A.2    Cunard, R.3
  • 17
    • 84872400230 scopus 로고    scopus 로고
    • Kn ockout of na-glucose transporter sglt2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
    • Vallon V, Rose M, Gerasimova M, et al. (2013). Kn ockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol-Renal Physiol 304:F156-67.
    • (2013) Am J Physiol-Renal Physiol , vol.304 , pp. F156-F167
    • Vallon, V.1    Rose, M.2    Gerasimova, M.3
  • 18
    • 84861497142 scopus 로고    scopus 로고
    • Sodium glucose co-tr ansporter 2 (sglt2) inhibitors: Novel antidiabetic agents
    • Washburn WN. (2012). Sodium glucose co-tr ansporter 2 (SGLT2) inhibitors: novel antidiabetic agents. Expert Opin Therapeut Patents 22:483-94.
    • (2012) Expert Opin Therapeut Patents , vol.22 , pp. 483-494
    • Washburn, W.N.1
  • 19
    • 84875447468 scopus 로고    scopus 로고
    • In vitro-in vivo correlation of the inhibition potency of so dium-glucose cotransporter inhibitors in rat: A pharmacokinetic and pharmacodynamic modeling approach
    • Yamaguchi K, Kato M, Suzuki M, et al. (2013). In vitro-in vivo correlation of the inhibition potency of so dium-glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach. J Pharmacol Exp Ther 345:52-61.
    • (2013) J Pharmacol Exp Ther , vol.345 , pp. 52-61
    • Yamaguchi, K.1    Kato, M.2    Suzuki, M.3
  • 20
    • 84896787255 scopus 로고    scopus 로고
    • Metabolism and mass balance of sglt2 inhibitor tofogliflozin following oral administration to humans
    • Zell M, Husser C, Kuhlmann O, et al. (2013). Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans. Xenobiotica 44:369-78.
    • (2013) Xenobiotica , vol.44 , pp. 369-378
    • Zell, M.1    Husser, C.2    Kuhlmann, O.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.